Novo Is Down 40%-But the Obesity Franchise Still May Be Worth More Than the Market Thinks

Novo's selloff looks more like a pricing panic than a franchise collapse

Novo's decline looks less like a fair verdict on the obesity business and more like a market resetting expectations too aggressively. Shares have fallen nearly 20% in 2026, and more than $400 billion has been erased from market value since the 2024 peak. That kind of drawdown often reflects fear that a drug category's pricing rules have broken, even when demand has not fully gone away.

Q1 headlines were noisy, but the quarter was not a collapse

Part of the confusion was accounting-related. At first glance, Q1 looked explosive: reported sales increased 32% and reported operating profit increased by 65% at CER. But that picture was distorted by a 340B provision reversal. The cleaner operating view was darker but still far from broken: adjusted sales fell 4% and adjusted operating profit fell 6%. That fits a reset year driven by pricing pressure, not a sudden disappearance of demand.

Why the next few updates matter more than the headline beat

Investors are now testing whether volume growth can partially offset lower realized prices. That is a reasonable standard. Even after the pullback, Obesity care sales grew 22% globally, and the business still has international growth and product-format breadth to draw on. If upcoming updates show that demand remains sizeable even with weaker economics, the stock may not need a perfect story to recover some value.

Pricing power weakened first; patient demand did not

The clearest change this quarter was not a flattening demand curve. It was lower monetization of that demand.

Geography shows where the pressure hit

The regional split tells the story. Adjusted obesity care sales increased by 22% at CER globally, while US Operations adjusted sales decreased by 11% at CER and adjusted gross margin was 80.6%, down from 83.5%. That pattern is more consistent with a price reset than with a collapse in patient interest.

Novo's own reporting says adjusted sales declined because lower realized prices outweighed GLP-1 volume growth across geographies, while US sales fell for the same reason. International Operations still grew by 6% at CER, driven by higher volumes. That does not prove the pricing environment is fixed, but it does suggest the obesity franchise is still finding demand even as the economics soften.

The real debate: lower multiple, or lower quality?

Bears see damaged pricing power and argue the obesity franchise should trade more like a mature, widely consumed therapy. That view has gained ground because analysts have started revising expectations amid price erosion, with some 2030 forecasts moving toward roughly $100 billion from earlier, higher estimates.

Bulls do not need to argue that the old economics are intact. They only need to show that lower prices have not destroyed the franchise's scale, longevity, or relevance. If volume growth can partly absorb pricing pressure, Novo may deserve a lower multiple for a while rather than a permanently damaged valuation.

Oral uptake, higher-dose data, and international rollout keep the case alive

A tougher pricing environment does not automatically mean the business is worth far less. If Novo can reach more patients, keep treatment going longer, and diversify across formats and regions, fair value can still be meaningful even with weaker per-unit economics.

The Wegovy pill is broadening the franchise

Novo is no longer relying on a single delivery model. The Wegovy pill reached more than 1 million users within 16 weeks, and company data show more than 2 million total prescriptions since launch with weekly prescriptions exceeding 200,000 by mid-April. That does not settle the valuation debate, but it does show the oral format is gaining traction early.

Higher-dose results still support clinical upside

The clinical profile also remains supportive. Wegovy 7.2 mg delivered 20.7% mean weight loss in trials. If higher potency helps keep patients on therapy, the franchise may remain clinically relevant even if market-size expectations have come down. Reuters reports that analysts have trimmed 2030 obesity-market expectations to about $100 billion, which is smaller than earlier optimism but still large enough for a leader with Novo's reach.

International expansion is the second lever

Global rollout matters because it can reduce reliance on U.S. pricing alone. Novo says the first Wegovy pill launches outside the US are expected during the second half of 2026. If those launches progress smoothly, investors can model a longer runway for volume growth even if U.S. margins stay under pressure.

What would strengthen or weaken the case from here

Valuation now depends less on whether the business is still growing and more on whether growth can outlast the pricing reset. Novo did report a first-quarter adjusted operating profit above expectations, but investors stayed cautious because one profit beat does not prove that volumes can consistently outrun lower realized prices.

After a share price slide that erased more than $400 billion, the market is asking for repeated evidence that this is a margin reset inside a still-sizeable obesity business, not a permanent downgrade in franchise quality.

The main signals to watch

• Pill traction: Whether total weekly prescriptions exceeded 200,000 can hold up as launch momentum fades and competition intensifies.
• International offset: Whether International Operations sales increased by 6% at constant exchange rates can keep expanding as a buffer against weaker U.S. pricing.
• Margin path: Whether adjusted gross margin was 80.6%, down from 83.5% starts to stabilize rather than weaken further.
• Forecast discipline: Whether analysts revise obesity drug market forecasts due to price erosion keep drifting lower or begin to settle.

If those signals improve or at least stop worsening, the current selloff may prove more punitive than the underlying business deserves.